Company intelligence / Profile preview

OrSense

Petah Tikva, Central District, Israelorsense.com ↗

Ownership: Private
Employees: ~28
Development stage: Commercial

Overview

OrSense’s non-invasive hemoglobin measurement devices have demonstrated accuracy comparable to invasive point-of-care devices in clinical trials for anemia screening and hemorrhage detection. The NBM 200MP system has FDA clearance and CE approval and has been tested on thousands of patients in the US and Europe. Clinical studies show reliable performance even under challenging conditions such as hemorrhage or pregnancy[3][5][7].

Therapeutic areas: Infectious DiseasesEndocrinologyHematology
Modalities: Device
Industry: Physiological Monitoring

Partnerships

implemented at major hospitals including Children’s Hospital Los Angeles

Beyond the preview

Go deeper on OrSense.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OrSense.

Explore the full profile